# Amgen, Inc. (NASDAQ: AMGN), Thousand Oaks, CA – FDA Inspections

Source: https://www.keypedia.com/companies/amgen-inc/85ec512e-6991-42ee-9cd5-148cfe0ed3e8

> Inspection records and compliance data for Amgen, Inc. in Thousand Oaks, California. 30 FDA inspections on record (1 OAI), 6 Form 483s, 1 warning letter, last inspected August 07, 2025. Publicly traded as NASDAQ: AMGN.

---

## Details

- Name: Amgen, Inc.
- FEI Number: 2026154
- Address Line 1: 1 Amgen Center Dr
- City: Thousand Oaks
- State: California
- Zip Code: 91320
- Country Name: United States
- Address: 1 Amgen Center Dr, Thousand Oaks, California 91320, United States
- Country: United States

## Stock

- Stock ticker: AMGN
- Exchange: NASDAQ
- Share price: $467.06
- Market cap: $252.6B
- Price as of: November 13, 2026

## Related Documents

- [483 - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/483/amgen-inc/a1384fcb-8ceb-4fff-b827-7aedea6283ba) — source: FDA, date: Invalid Date
- [483 - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/483/amgen-inc/0f69de0e-3c79-4e80-8482-84801428e3f1) — source: FDA, date: Invalid Date
- [483 - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/483/amgen-inc/3fd38f88-0f27-4242-95c6-59ba05cffdc8) — source: FDA, date: Invalid Date
- [CRL - Amgen, Inc. - Unknown Date](https://www.keypedia.com/records/crl/amgen-inc/b96aeb10-a857-41b8-8fa5-8ca2465cce5a) — source: FDA, date: Invalid Date
- [FDA Inspection 1278976 - Amgen, Inc. - 2025-08-07](https://www.keypedia.com/records/fda_inspections/amgen-inc/d97d8a62-a229-4000-9007-f563754eede5) — source: FDA, date: August 7, 2025
- FDA Inspection 1278976 - Amgen, Inc. - 2025-08-07 — classification: No Action Indicated (NAI), source: FDA, date: August 7, 2025
- [483 - Amgen, Inc. - 2025-03-13](https://www.keypedia.com/records/483/amgen-inc/f158a248-7fa2-44df-9ef9-74b5f972894b) — source: FDA, date: March 13, 2025
- [FDA Inspection 1256132 - Amgen, Inc. - 2025-03-13](https://www.keypedia.com/records/fda_inspections/amgen-inc/8601b5a4-a27d-4f90-9399-1e0398db8be7) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 13, 2025
- [483 - Amgen, Inc. - 2024-02-06](https://www.keypedia.com/records/483/amgen-inc/e9edaa4a-6d46-4674-882b-fc862d99421c) — source: FDA, date: February 6, 2024
- [FDA Inspection 1240449 - Amgen, Inc. - 2024-02-06](https://www.keypedia.com/records/fda_inspections/amgen-inc/fe67a98f-c816-4387-bbd9-9d30c82ae96a) — source: FDA, date: February 6, 2024
- FDA Inspection 1220409 - Amgen, Inc. - 2023-09-14 — classification: No Action Indicated (NAI), source: FDA, date: September 14, 2023
- [483 - Amgen, Inc. - 2019-12-13](https://www.keypedia.com/records/483/amgen-inc/38972f72-b21d-41b2-bb8b-25e715f425e9) — source: FDA, date: December 13, 2019
- [EIR - Amgen, Inc. - 2019-12-13](https://www.keypedia.com/records/eir/amgen-inc/7155ec06-4efb-4490-8b2d-eecd030871d1) — source: FDA, date: December 13, 2019
- [FDA Inspection 1112791 - Amgen, Inc. - 2019-12-13](https://www.keypedia.com/records/fda_inspections/amgen-inc/f7c02d35-9f41-4022-9b49-996bf75204ed) — classification: Voluntary Action Indicated (VAI), source: FDA, date: December 13, 2019
- [FDA Inspection 1046609 - Amgen, Inc. - 2018-03-16](https://www.keypedia.com/records/fda_inspections/amgen-inc/d0e046ab-e62b-4cd7-94ba-97f0f5fc5292) — source: FDA, date: March 16, 2018
- [FDA Inspection 1036564 - Amgen, Inc. - 2017-11-03](https://www.keypedia.com/records/fda_inspections/amgen-inc/f8dc1884-c613-4f29-825e-5c57b648bb33) — source: FDA, date: November 3, 2017
- FDA Inspection 1040847 - Amgen, Inc. - 2017-10-03 — source: FDA, date: October 3, 2017
- FDA Inspection 1028320 - Amgen, Inc. - 2017-08-21 — classification: No Action Indicated (NAI), source: FDA, date: August 21, 2017
- [483 - Amgen, Inc. - 2017-05-16](https://www.keypedia.com/records/483/amgen-inc/a23066f5-45d7-4383-9490-ac82f211990c) — source: FDA, date: May 16, 2017
- [WARNING_LETTER - Amgen, Inc. - 2013-06-17](https://www.keypedia.com/records/warning_letter/amgen-inc/980f4f23-54ec-4bfd-b859-cf7b7d38566c) — source: FDA, date: June 17, 2013

## Related Companies

- [FUJIFILM Diosynth Biotechnologies Denmark ApS](https://www.keypedia.com/companies/fujifilm-diosynth-biotechnologies-denmark-aps/513b3c42-1517-43bc-936a-d3edd26bed70)
- [Eli Lilly & Company](https://www.keypedia.com/companies/eli-lilly-company/fc56eed7-d261-4de3-865e-c2aa54162adf)
- [Cilag AG](https://www.keypedia.com/companies/cilag-ag/acb7f670-89b9-4e40-a784-ed06b0282362)
- [Amgen Manufacturing Ltd](https://www.keypedia.com/companies/amgen-manufacturing-ltd/cecb788c-4cd6-4c26-9331-7b68b4f12369)
- [Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany](https://www.keypedia.com/companies/halo-pharmaceutical-inc-dba-cambrex-whippany/1464443d-ae5a-4d06-959c-d1ccb1b213a2)
- [Biological E. Limited](https://www.keypedia.com/companies/biological-e-limited/a02640a2-3dc0-448e-9a4f-df7e189939e4)
- [Sumitomo Dainippon Pharma Co., Ltd.](https://www.keypedia.com/companies/sumitomo-dainippon-pharma-co-ltd/40ead027-5fd5-4deb-a37b-40301cffd612)
- [Cipla Limited](https://www.keypedia.com/companies/cipla-limited/ca77117b-0afe-4b51-bdc2-82ee1e242ec8)
- [ALK-Abello, Inc.](https://www.keypedia.com/companies/alk-abello-inc/b626f86d-b379-45aa-96d2-0661e9d1c981)
- [Latina Pharma S.p.A.](https://www.keypedia.com/companies/latina-pharma-spa/9cb7e758-39a0-4b4c-bfad-93d1468f5d38)

## Related Officers

- [Investigator](https://www.keypedia.com/people/roger-f-zabinski/87e05838-f8b5-489a-8db7-6669e68a2c2e)
- [Esther C. Broner](https://www.keypedia.com/people/esther-c-broner/5df7ca72-a21f-4586-a5e0-8a782045281c)
- [Zhong Li](https://www.keypedia.com/people/zhong-li/18545b20-7fa5-4850-9dd4-cffb40c41f8d)
- [Marc Kubasak, PhD](https://www.keypedia.com/people/marc-kubasak-phd/0022703d-5fa9-4022-9d76-821be46e8f5d)